Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.172
-0.013 (-7.07%)
At close: Jun 26, 2026, 4:00 PM EDT
0.170
-0.002 (-1.28%)
After-hours: Jun 26, 2026, 7:57 PM EDT

Company Description

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus.

The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names.

It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).

In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand.

It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.

Cosmos Health Inc.
Cosmos Health logo
Country Greece
Founded 2009
IPO Date Dec 13, 2013
Industry Medical Distribution
Sector Healthcare
Employees 163
CEO Grigorios Siokas

Contact Details

Address:
5 Agiou Georgiou Str, Pilea
Thessaloniki, 55438
Greece
Phone 312 536 3102
Website cosmoshealthinc.com

Stock Details

Ticker Symbol COSM
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001474167
CUSIP Number 221413206
ISIN Number US2214133058
Employer ID 27-0611758
SIC Code 5122

Key Executives

Name Position
Grigorios Siokas Chairman and Chief Executive Officer
Georgios Terzis Chief Financial Officer
Nikolaos Bardakis Chief Operating Officer
Demetrios G. Demetriades Secretary and Independent Director
Prof. Dimitrios Trafalis Head of Oncology

Latest SEC Filings

Date Type Title
Jun 8, 2026 S-3/A [Amend] Registration statement under Securities Act of 1933
Jun 5, 2026 SCHEDULE 13G/A Filing
Jun 5, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 2, 2026 DEF 14A Other definitive proxy statements
May 22, 2026 PRE 14A Other preliminary proxy statements
May 22, 2026 8-K Current Report
May 20, 2026 10-Q Quarterly Report
May 15, 2026 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
May 11, 2026 RW Filing
Apr 24, 2026 SCHEDULE 13G/A Filing